Project description:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with an umet need for improved therapies. We explored the potentially synergic combination of MDM2 inhibition and Bcl-2, Bcl-xL inhibition through cotreatment of T-ALL models with idasanutlin and navitoclax. In order to understand the early transcriptional changes induced by this combination therapy, we performed RNA sequencing on drug treated cells.

2023-10-16 | GSE240444 | GEO

Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Project description: Not available

| S-EPMC7672533 | biostudies-literature